Bromantane (Ladasten): What It Is and What the Research Shows

A grounded compound reference on bromantane (Ladasten, ADK-709): an adamantane-derivative actoprotector that raises dopamine synthesis via tyrosine hydroxylase, combines mild stimulant and anxiolytic effects, is approved only in Russia for asthenia, and remains a research chemical in the US. Covers verified mechanism, human trials, study doses, community practice, and safety.

bromantane is an adamantane-derivative compound that Russian researchers class as an "actoprotector": it pairs a mild stimulant, anti-fatigue effect with an anxiolytic (anti-anxiety) effect, and the Russian trial data report it does this without the tolerance, crash, or withdrawal that follow conventional stimulants PMID: 19491814. Its signature mechanism is unusual. Instead of dumping or blocking reuptake of dopamine, it appears to increase dopamine *synthesis* by upregulating the enzyme tyrosine hydroxylase PMID: 17854844. It is approved and sold in Russia as Ladasten for asthenia and neurasthenia, but it is not approved by the FDA or EMA, so in the US it is an unapproved research chemical, sold for research use only.

This is the *compound* reference. If you came looking for how bromantane is combined with sulbutiamine as a daily nootropic protocol, that lives in a separate write-up: bromantane and sulbutiamine stack explained. Everything below is about the molecule itself: what it is, what the studies actually found, and where the evidence is thin.

Quick facts

What bromantane actually is

Bromantane is a small synthetic molecule built on an adamantane cage, the same structural family as amantadine and memantine PMID: 17854844. That family matters. Adamantanes tend to touch dopaminergic and glutamatergic systems, and bromantane is no exception. Russian pharmacology has a specific word for its profile, "actoprotector," meaning a drug meant to preserve physical and mental performance under fatigue, heat, or stress without acting like a hard stimulant.

The interesting part is the combination. Most things that make you more activated also make you more anxious. Bromantane reads, in the Russian literature, as doing the opposite pairing: mild activation *plus* reduced anxiety in the same compound PMID: 19491814. That two-in-one profile is the reason it gets attention outside Russia. It is also the reason to be careful, because "unusual and appealing" is exactly the kind of claim that deserves the independent replication it mostly hasn't gotten yet.

How bromantane works

The headline mechanism is that bromantane raises dopamine by making more of it, not by forcing release. In rats, a single 50 mg/kg dose differentially regulated tyrosine hydroxylase (the rate-limiting enzyme for dopamine synthesis) at both the mRNA and protein level, along with dopamine and L-DOPA content, across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum, and hippocampus PMID: 17854844. A separate neurochemical study used NSD-1015, an aromatic-L-amino-acid decarboxylase inhibitor, and found bromantane increased L-DOPA (dopamine's precursor) in nearly every brain structure except the hippocampus, which points to a predominant action on tyrosine hydroxylase and a selective effect on the dopaminergic system PMID: 20408420.

Why does the synthesis-versus-release distinction matter? A synthesis-upregulation mechanism builds up over hours to days rather than spiking and crashing, which fits both the slow onset reported by users and the low tolerance/withdrawal seen in the trials.

It is not purely dopaminergic. Bromantane also shifts serotonin (raising 5-HT and its metabolites in some regions while lowering them in others), and downstream it activates the ERK1/ERK2 MAP-kinase cascade and increases gene expression of the neurotrophins BDNF and NGF in rat striatum, hypothalamus, and hippocampus PMID: 22803074. In hippocampal slices, 10 microM converted short-term potentiation into long-term potentiation through protein-synthesis- and D1/D5-dopamine-receptor-dependent mechanisms; the effect was blocked by the protein-synthesis inhibitor anisomycin and by the D1/D5 antagonist SCH23390 PMID: 17854844. There is also a consistent immunomodulatory signal. In rodent stress and depression-like models, bromantane lowered pro-inflammatory cytokines like TNF-alpha and IL-6 and normalized T-lymphocyte subpopulations PMID: 22803040PMID: 24771370.

What the research shows about effects

Bromantane's best human evidence is for asthenia and fatigue. In a randomized, blind, placebo-controlled study in neurasthenia, a 28-day course of ladasten monotherapy (followed by a one-week placebo run-out) beat placebo on the rate and degree of asthenic-symptom reduction, showed the combined psychostimulant-plus-anxiolytic action, and produced no withdrawal syndrome, which the authors read as a lack of addictive potential PMID: 19491814. A much larger 28-center Russian study of 728 analyzable patients with asthenic disorders reported 76.0% responders on the CGI-S scale and 90.8% on the CGI-I scale after 50-100 mg/day for 28 days, with the antiasthenic effect appearing by day 3 and holding a month after withdrawal; adverse effects showed up in only 3% of patients PMID: 21322821.

There is a fatigue signal outside psychiatry, too. In a controlled study, adding ladasten 100 mg/day (alongside ondansetron and agomelatine) improved fatigue and weakness in incurable cancer patients versus standard therapy PMID: 26087610. On the mechanism-in-humans side, a single oral dose in 10 healthy volunteers shifted the EEG toward a profile typical of moderate psychostimulant, antiamnestic, and antihypoxic drugs (more mid-frequency alpha, less delta and beta1) and improved operator functional state under fatigue, without changing subjective state in rested men PMID: 10998997.

One honest caveat runs through all of this: the effect is not linear with dose. In a rat Irwin-protocol study, doses of 30-300 mg/kg stimulated behavior and motor activity while doses above 600 mg/kg suppressed them, a biphasic, inverted-U response tied to central dopamine stimulation plus cholinergic suppression PMID: 12124651. More is not better.

Study and label doses

Report these as facts from the studies and Russian labeling, not as instructions. Doses are per-study; this guide is educational, not medical advice.

How the research community uses it

Outside Russia, bromantane circulates as a gray-market nootropic, and the community discussion is remarkably consistent with the pharmacology. Described in aggregate and paraphrased (no verbatim quotes, no named users): people tend to frame it as a stimulant that also lowers anxiety, a calm, confident "drive" that makes tedious work tolerable and takes the edge off social anxiety, rather than a jittery caffeine push.

Onset is widely reported as slow. Users say the activating effect builds over roughly 1.5-2 hours after an oral dose and can last most of the day, with anti-fatigue benefit accumulating over the first one to three days of use. That slow, cumulative pattern is what you would expect from a synthesis-upregulation mechanism rather than acute release. A recurring anecdotal theme is a bell-curve, "less is more" dose-response: many report that pushing past their sweet spot blunts the benefit or brings a dull headache, restlessness, or next-day grogginess instead of more stimulation. That mirrors the biphasic rodent data, though it remains anecdotal in humans PMID: 12124651. The most common self-reported downside is disrupted sleep when it's dosed too late in the day, which lines up with the mild insomnia, headache, and irritability seen at about a 3% rate in the Russian trials PMID: 21322821.

Bromantane also shows up as a stack base, most often paired with sulbutiamine for added cholinergic "drive." That combination is its own topic; see the bromantane and sulbutiamine stack explainer for how the community runs it. For the compound data page on this site, see bromantane.

Safety, regulatory status, and evidence limits

Regulatory status first, because it drives everything else. Bromantane is approved and marketed only in Russia (as Ladasten) for asthenia and neurasthenia. It is not approved by the FDA or EMA. In the US and EU it is an unapproved research chemical with no human safety oversight and no standardized dosing outside Russia, which is why the research-chemical vial or nasal solution you can find online is not an approved drug.

The evidence quality is a real limitation, not a footnote. Nearly all efficacy and mechanism data come from Russian human trials and rodent studies out of a small number of groups (much of it linked to the Zakusov Institute). Independent Western replication is scarce, many human trials are open-label or single-blind, abstracts are often in Russian, and long-term human safety data are thin. The appealing "no tolerance, no withdrawal" claims are promising but not independently confirmed.

A few concrete safety points:

• Anti-doping. Bromantane is a WADA-prohibited substance and was behind high-profile disqualifications at the 1996 Olympics. Anyone subject to drug testing should stay away from it.
• Adverse events. In the Russian trials, adverse events were mild and infrequent (about 3%, typically insomnia, headache, irritability), with under 1% discontinuation and no serious events. But these were short, 28-day studies, so chronic-use safety is unknown PMID: 21322821.
• Biphasic dosing. Low-to-moderate doses stimulate while very high doses suppress activity in animals, so escalating the dose is likely to reduce benefit and add side effects PMID: 12124651.
• Reproductive safety. Data exist only in rats, with dose-dependent, non-monotonic effects on litter size and pup development and no major malformations, but human reproductive safety is unestablished PMID: 11348840. Avoid in pregnancy, breastfeeding, and in anyone who could become pregnant.
• Drug interactions. Its dopaminergic action warrants caution with psychiatric conditions and with other dopaminergic or stimulant drugs.

None of this is medical advice. It is a summary of what the literature reports.

Sourcing and where to get it

Because most bromantane supply is gray-market research-chemical material, purity and identity vary a lot, and a certificate of analysis (COA) tied to the specific lot is the minimum bar. If you're evaluating any research-compound vendor, learn to read the paperwork first: how to read a peptide COA and the vendor scorecard walk through what a real, per-lot COA should show. General handling basics live in the reconstitution guide and the storage guide.

BHG Labs lists bromantane as a coming-soon atomized (nasal) solution; it is not yet purchasable, so there's no buy link. When it goes live, the reader code REDDIT is worth 10% off. *Independent vendor; BodyHackGuide may earn a commission.* BHG Labs is one reputable COA-per-lot option to compare, not the only one. See the BHG Labs vendor page and verify COAs yourself before trusting any source. ("BHG" here means the vendor BHG Labs, not BodyHackGuide.)

No comments yet — be the first to share your thoughts!

Weekly drops, weekly research

New guides, price-drop alerts, and reader-submitted protocols. One email a week. Unsubscribe anytime.

Email addressSubscribe

No spam. Unsubscribe anytime.

Related Articles